Novavax Granted Provisional Registration For Nuvaxovid As Booster In Australia

Novavax, Inc. (NVAX) announced the Australian Therapeutic Goods Administration has granted provisional registration of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine as a booster in individuals aged 18 and over. The provisional registration was based on data from Novavax' phase 2 trial conducted in Australia, from a separate phase 2 trial conducted in South Africa, and from the UK-sponsored COV-BOOST trial. The company's sponsor in Australia is Biocelect Pty. Ltd.

"We are pleased to be able to offer the first protein-based COVID-19 vaccine registered for use as both a primary series and now booster regardless of previous vaccine history," said Stanley Erck, CEO, Novavax.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT